Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | PARP1 | P09874 | 11/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959657 | 0.86 | SIGMAR1 (0.51) | SIGMAR1PARP1 | |
| SCHEMBL7964116 | 0.85 | PARP1 (0.45) | SIGMAR1PARP1 | |
| SCHEMBL7960204 | 0.85 | SIGMAR1 (0.52) | SIGMAR1PARP1HTR1A | |
| SCHEMBL7959426 | 0.85 | PARP1 (0.46) | SIGMAR1PARP1 | |
| SCHEMBL7961243 | 0.85 | SIGMAR1 (0.54) | SIGMAR1PARP1HTR1A | |
| SCHEMBL7963856 | 0.84 | SIGMAR1 (0.53) | SIGMAR1PARP1HTR1A | |
| SCHEMBL7959607 | 0.83 | PARP1 (0.41) | SIGMAR1PARP1HTR1A | |
| SCHEMBL7949114 | 0.83 | SIGMAR1 (0.42) | SIGMAR1PARP1HTR1A | |
| SCHEMBL7957068 | 0.83 | PARP1 (0.44) | SIGMAR1PARP1 | |
| SCHEMBL7949615 | 0.81 | PARP1 (0.39) | SIGMAR1PARP1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |